{{Rsnum
|rsid=4792311
|Gene=ELAC2
|Chromosome=17
|position=13011692
|Orientation=plus
|ReferenceAllele=C
|MissenseAllele=T
|GMAF=0.2066
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=ELAC2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 9.7 | 49.6 | 40.7
| HCB | 0.0 | 5.8 | 94.2
| JPT | 0.0 | 3.5 | 96.5
| YRI | 4.1 | 34.0 | 61.9
| ASW | 1.8 | 38.6 | 59.6
| CHB | 0.0 | 5.8 | 94.2
| CHD | 0.0 | 7.3 | 92.7
| GIH | 5.0 | 37.6 | 57.4
| LWK | 5.5 | 36.4 | 58.2
| MEX | 3.4 | 44.8 | 51.7
| MKK | 12.2 | 39.7 | 48.1
| TSI | 9.8 | 33.3 | 56.9
| HapMapRevision=28
}}{{omim
|desc=PROSTATE CANCER, SUSCEPTIBILITY TO
|id=605367
|rsnum=4792311
|variant=0001
}}

{{ClinVar
|rsid=4792311
|Reversed=0
|FwdREF=G
|FwdALT=A
|REF=G
|ALT=A
|RSPOS=12915009
|CHROM=17
|GMAF=0.206
|dbSNPBuildID=111
|SSR=0
|SAO=1
|VP=0x05016800000015051f110100
|GENEINFO=ELAC2:60528
|GENE_NAME=ELAC2
|GENE_ID=60528
|WGT=0
|VC=SNV
|CLNALLE=1
|CLNHGVS=NC_000017.10:g.12915009G>A
|CLNORIGIN=1
|CLNSIG=5
|Tags=PM;PMC;SLO;VLD;G5;HD;GNO;KGPhase1;KGPilot123;KGPROD;OTHERKG;PH3;LSD;OM
|CAF=0.7934; 0.2066
|CLNACC=RCV000005358.1
|CLNDBN=Prostate cancer, hereditary, 2
|CLNDSDB=MedGen:OMIM:Orphanet
|CLNDSDBID=CN130472:614731:1331
|CLNSRC=OMIM Allelic Variant
|CLNSRCID=605367.0001
|COMMON=1
|Disease=Prostate cancer
}}

{{PMID|18375959|OA=1
}} Sequence variants of elaC homolog 2 (Escherichia coli) (ELAC2) gene and susceptibility to prostate cancer in the Health Professionals Follow-Up Study.

{{PMID|19379518|OA=1
}} Development of a fingerprinting panel using medically relevant polymorphisms.

{{PMID|19567509|OA=1
}} Genetic variants and prostate cancer risk: candidate replication and exploration of viral restriction genes.

{{PMID|20565774|OA=1
}} Population based allele frequencies of disease associated polymorphisms in the Personalized Medicine Research Project.

{{GET Evidence
|gene=ELAC2
|aa_change=Ser217Leu
|aa_change_short=S217L
|impact=pathogenic
|qualified_impact=Low clinical importance, Uncertain pathogenic
|inheritance=other
|quality_scores=Array
|dbsnp_id=rs4792311
|overall_frequency_n=2942
|overall_frequency_d=10758
|overall_frequency=0.273471
|n_genomes=40
|n_genomes_annotated=0
|n_haplomes=42
|n_articles=4
|n_articles_annotated=4
|qualityscore_in_silico=1
|qualitycomment_in_silico=Y
|qualityscore_case_control=3
|qualityscore_familial=0
|qualitycomment_familial=Y
|qualityscore_severity=2
|qualitycomment_severity=Y
|qualityscore_treatability=0
|qualitycomment_treatability=Y
|gene_in_genetests=Y
|in_omim=Y
|pph2_score=0.025
|genetests_testable=Y
|nblosum100=6
|max_or_disease_name=Prostate cancer
|max_or_case_pos=178
|max_or_case_neg=1116
|max_or_control_pos=242
|max_or_control_neg=1262
|max_or_or=0.832
|autoscore=3
|webscore=N
|n_web_uneval=8
|variant_evidence=0
|clinical_importance=0
|summary_short=Reported to be associated with increased susceptibility to prostate cancer, but later studies weaken the hypothesis. Xu et al.'s meta-analysis concludes that there is a small but significant increased risk (OR = 1.13). Assuming a lifetime risk of 16% for prostate cancer we calculate this leads to an increased risk of ~1.5% (17.5% total).
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}